Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tretoquinol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 5/20 | 0.97 |
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 0.97 |
| ▸ | ADRB3 known ✓ | P13945 | 3/20 | 0.97 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.97 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.97 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.97 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.97 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.64 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 6/20 | 0.97 |
| ▸ | DHFR | P00374 | 1/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ALPL | P05186 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tretoquinol SCHEMBL30537714 | 1.00 | TBXA2R (0.97) | TBXA2RADRB2ADRB1ADRB3HTR1A | |
| Tretoquinol SCHEMBL29966739 | 1.00 | TBXA2R (0.97) | TBXA2RADRB2ADRB1ADRB3HTR1A | |
| Tretoquinol SCHEMBL11040376 | 0.99 | TBXA2R (0.95) | TBXA2RADRB2ADRB1ADRB3HTR1A | |
| Tretoquinol SCHEMBL249003 | 0.99 | TBXA2R (1.00) | TBXA2RADRB2ADRB1ADRB3HTR1A | |
| Tretoquinol SCHEMBL249002 | 0.99 | TBXA2R (1.00) | TBXA2RADRB2ADRB1ADRB3HTR1A | |
| Tretoquinol SCHEMBL29383882 | 0.99 | TBXA2R (1.00) | TBXA2RADRB2ADRB1ADRB3HTR1A | |
| Tretoquinol SCHEMBL9053034 | 0.97 | TBXA2R (0.97) | TBXA2RADRB2ADRB1ADRB3HTR1A | |
| Tretoquinol SCHEMBL1604695 | 0.97 | TBXA2R (0.97) | TBXA2RADRB2ADRB1ADRB3HTR1A | |
| SCHEMBL12635396 | 0.88 | ADRB2 (0.80) | TBXA2RADRB2ADRB1ADRB3HTR1A | |
| SCHEMBL17713983 | 0.88 | ADRB2 (0.80) | TBXA2RADRB2ADRB1ADRB3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101563381-A | Adhesive forming compositions and adhesive blends obtained therefrom | MOMENTIVE PERFORMANCE MAT INC (US) | 2009-10-21 | — | — | CN | claimed |
| EP-0580860-B2 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 2004-12-15 | — | — | EP | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| US-12304913-B2 | Dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2025-05-20 | — | — | US | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-3885347-B1 | DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE CORP (JP) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023190826-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | 学校法人 高崎健康福祉大学 | 2023-10-05 | — | — | WO | disclosed |
| WO-2022124243-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | 東和薬品株式会社 | 2022-06-16 | — | — | WO | disclosed |
| US-20220002303-A1 | DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE CORPORATION (JP) | 2022-01-06 | — | — | US | disclosed |
| EP-3885347-A1 | DIHYDROPYRROLOPYRAZOLE DERIVATIVE | Ube Industries, Ltd. (JP) | 2021-09-29 | — | — | EP | disclosed |
| US-10799593-B2 | Nanodiamond particle complexes | NORTHWESTERN UNIVERSITY (US) | 2020-10-13 | — | — | US | disclosed |
| US-4443497-A | DISSOLVING, COATING, SOLVENTS, POLYMER, ETHYL CELLULOSE, ANTICOAGULANTS, DRUGS | TANABE SEIYAKU CO., LTD. (JP) | 1984-04-17 | — | — | US | disclosed |
| EP-0099109-A1 | Process for preparing free-flowing ethylcellulose microcapsules | Tanabe Seiyaku Co., Ltd. (JP) | 1984-01-25 | — | — | EP | disclosed |
| US-4411933-A | CYCLOHEXANE, ORGANOSILICON POLYMER, DISPERSION, CORES | TANABE SEIYAKU CO., LTD. (JP) | 1983-10-25 | — | — | US | disclosed |
| US-4389331-A | Process for preparing pharmaceutically active compound-containing microcapsules | TANABE SEIYAKU CO., LTD. (JP) | 1983-06-21 | — | — | US | disclosed |
| EP-0077956-A1 | Enteric microcapsules and process for the preparation thereof | Tanabe Seiyaku Co., Ltd. (JP) | 1983-05-04 | — | — | EP | disclosed |
| EP-0038979-A1 | Process for preparing ethylcellulose microcapsules | Tanabe Seiyaku Co., Ltd. (JP) | 1981-11-04 | — | — | EP | disclosed |
| US-4218333-A | ETHYL CELLULOSE WALL-FORMING AGENT AND POLYISOBUTYLENE AS PHASE SEPARATION AGENT | TANABE SEIYAKU CO., LTD. (JP) | 1980-08-19 | — | — | US | disclosed |
| US-4016100-A | PHOSPHOLIPID DISPERSION, FREEZING, THAWING | TANABE SEIYAKU CO., LTD. (JA) | 1977-04-05 | — | — | US | disclosed |
| US-3994974-A | BRONCHODILATORS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002303-A1 | DIHYDROPYRROLOPYRAZOLE DERIVATIVE | CBR3, SLC13A3, CYP3A5 | ADRB2 62/4885ADRB1 140/4885ADRB3 12/4885 |
| US-12304913-B2 | Dihydropyrrolopyrazole derivative | CBR3, SLC13A3, CYP3A5 | ADRB2 62/4885ADRB1 140/4885ADRB3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.